Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Current Deferred Revenue (2024 - 2025)

Exagen's Current Deferred Revenue history spans 2 years, with the latest figure at $675000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 7.91% year-over-year to $675000.0; the TTM value through Dec 2025 reached $675000.0, down 7.91%, while the annual FY2025 figure was $675000.0, 7.91% down from the prior year.
  • Current Deferred Revenue reached $675000.0 in Q4 2025 per XGN's latest filing, up from $600000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q2 2025 to a low of $600000.0 in Q3 2025.